Skip navigation
MedlinePlus Trusted Health Information for You U.S. National Library of MedicineNational Institutes of Health
Contact Us FAQs Site Map About MedlinePlus
español Home Health Topics Drug Information Medical Encyclopedia Dictionary News Directories Other Resources

 

Medical Encyclopedia

Other encyclopedia topics:  A-Ag  Ah-Ap  Aq-Az  B-Bk  Bl-Bz  C-Cg  Ch-Co  Cp-Cz  D-Di  Dj-Dz  E-Ep  Eq-Ez  F  G  H-Hf  Hg-Hz  I-In  Io-Iz  J  K  L-Ln  Lo-Lz  M-Mf  Mg-Mz  N  O  P-Pl  Pm-Pz  Q  R  S-Sh  Si-Sp  Sq-Sz  T-Tn  To-Tz  U  V  W  X  Y  Z  0-9 

Adrenoleukodystrophy

Printer-friendly versionEmail this page to a friend
Contents of this page:

Illustrations

Neonatal adrenoleukodystrophy
Neonatal adrenoleukodystrophy

Alternative names    Return to top

X-linked adrenoleukodystrophy; Melanodermic leukodystrophy; Neonatal adrenoleukodyrstophy; NALD

Definition    Return to top

Adrenoleukodystrophy describes any of several closely related inheritable disorders of the breakdown (metabolism) of certain fats (long chain fatty acids). These disorders affect the adrenal glands, nervous system, and testes.

Causes, incidence, and risk factors    Return to top

Adrenoleukodystrophy is transmitted as an X-linked trait (the neonatal form is by autosomal recessive transmission). It affects approximately 1 in 20,000 to 1 in 50,000 individuals from all races.

It results in the accumulation of long chain fatty acids in the nervous system, adrenal gland, and testes, which disrupts normal activity. There are several (seven recognized) different forms of the disease.

The neonatal form appears shortly after birth and includes seizures and delayed neurological development with death occurring in infancy or young childhood. The childhood cerebral form appears in mid-childhood (at 4-8 years), and the other forms appear during adolescence. About one-third of affected people develop neurological symptoms and about half develop abnormal adrenal function.

In the childhood form, early symptoms include hyperactivity, difficulty at school, difficulty understanding spoken material, deterioration of handwriting, crossed eyes (strabismus), and possibly seizures.

As the disease progresses, further signs of damage to the white matter of the brain appear and include changes in muscle tone, stiffness and contracture deformities, swallowing difficulties, and coma.

The other major component of adrenoleukodystrophy is the development of impaired adrenal gland function (similar to Addison disease). There is a deficiency of steroid hormones. This is a very significant development but one that can be adequately treated with corticosteroids.

Symptoms    Return to top

Neonatal type:

Childhood and adolescent type:

Progressive nervous system deterioration

Symptoms of adrenal gland failure

Signs and tests    Return to top

Treatment    Return to top

Adrenal dysfunction is treated with supplemental steroids (such as cortisol).

A specific treatment for adrenoleukodystrophy is not available, but a diet low in long chain fatty acids and the administration of special oils has been demonstrated to lower the blood levels of the long chain fatty acids. These oils are referred to as Lorenzo's oil, after the son of the family who discovered the treatment. This regimen is presently under evaluation for the treatment of adrenoleukodystrophy.

Expectations (prognosis)    Return to top

The childhood form of adrenoleukodystrophy is a progressive disease that leads to a vegetative state in approximately two years after neurologic symptoms develop. The child may live in this condition for as much as ten years until death occurs. The later onset forms are significantly less dangerous.

Complications    Return to top

Calling your health care provider    Return to top

Call your health care provider if your child develops symptoms suggestive of adrenoleukodystrophy or if you have a child with adrenoleukodystrophy who is experiencing increased difficulty.

Prevention    Return to top

Genetic counseling is recommended for prospective parents with a family history of adrenoleukodystrophy. The carrier state in females can be diagnosed in 85% of the cases using a very long fatty acid assay and a DNA probe study by specialized laboratories.

Intrauterine diagnosis of adrenoleukodystrophy is available and done by evaluation of cells from chorionic villus sampling or from amniotic cells (amniocentesis).

Update Date: 1/20/2004

Updated by: John Goldenring, M.D., M.P.H., Department of Pediatrics, Children's Hospital, San Diego, CA. Review provided by VeriMed Healtchare Network.

adam.com logo

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 2002 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.